Kathy (Moser) Sivils, Ph.D.
Adjunct Associate Professor, Department of Pathology, University of Oklahoma Health Sciences Center
Co-Director, Autoimmune and Cancer Biomarkers Group
Director, Sjögren’s Research Clinic, Director, Lupus Family Registry and Repository
Sjögren’s syndrome is a chronic disease that causes the immune system to attack moisture-producing glands. Two of the most common symptoms are dry eyes and dry mouth resulting from decreases in production of tears and saliva. That may not seem serious, but for those with the disease, it greatly impacts their quality of life. Sjögren’s can lead to scarring of the corneas and can be so severe that patients produce no tears. In the mouth, lack of saliva can lead to severe cavities, broken teeth and infections. It also changes the way things taste and can make it hard to speak, eat or swallow. Sjogren’s can also affect virtually any organ in the body. Other symptoms may include common ones such as fatigue, arthritis, and neurological problems, or more rare complications such as lymphoma. The disease is common but often unrecognized and affects about 3 million Americans.
In my lab, the main goal is to understand what causes Sjögren’s syndrome and to develop new ways to treat the disease. Our work focuses mostly on identifying the genetic roots of the disease. We’ve established a clinic with doctors who perform specialized testing and gather genetic samples from patients. With a large collection of samples from Sjögren’s patients, we can perform experiments to determine which genes they have in common and find out what role those genes play in the disease.
We are also working on another part of the Sjögren’s puzzle known as gene expression. This involves comparing how genes function between people with Sjögren’s and people who don’t have the disease. Using the latest technologies, we determine which genes are active and to what level they are working. With this information, we can identify patterns of genes that are behaving abnormally and then focus on why these specific genes lead to disease.
Our work in genetics also extends to lupus, another disease in which an unbalanced immune system gets confused and turns against a person’s own body. By doing large-scale screens of lupus patients’ DNA, we can identify common genes and how they’re related to the disease. Our goal, as with Sjögren’s, is to use this information to help devise better ways to treat patients suffering from this debilitating disease.
B.S., Oklahoma State University, 1987
Ph.D., University of Oklahoma Health Sciences Center, 1995
Post-doctoral training, Case Western Reserve University, Cleveland, OH
Honors and Awards
1990 Award for Outstanding Scientific Paper, Bretton Symposium on Autoimmunity, Brest, France
1992 Student Travel Award, American College of Rheumatology 56th Annual Scientific Meeting
1992-1995 OMRF Predoctoral Fellowship Award
1994 Course Scholarship, “Genetic Analysis Methods for Medical Researchers,” Duke University, Durham, NC
1995 Graduate Student Association Award for Outstanding Academic Achievement, OUHSC
1999-2000 NIH Postdoctoral Fellowship Award, Case Western Reserve University, Cleveland, OH
1999 Healthcare Provider of the Year, Oklahoma Lupus Association, Inc.
1999 New Investigator Award, Clinical Immunology Society
2002-2007 NIH Educational Loan Repayment Award
2003-2007 J.V. Satterfield Arthritis Investigator Award, National Arthritis Foundation
2004 Outstanding Graduate Student Abstract Award, Department of Medicine Research Day, University of Minnesota, Minneapolis, MN
2004 Sjögren’s Syndrome Foundation Outstanding Abstract Award, Honorable Mention, American College of Rhematology 68th Annual Meeting
2006 Sjögren’s Syndrome Foundation Ethel Baxter Award for Outstanding Abstract
2008 Sjögren’s Syndrome Foundation Healthcare Professional Leadership Award
2008 Merrick Award for Outstanding Research, OMRF
2014 Edward L. and Thelma Gaylord Prize for Scientific Achievement
Editorial board, Genes and Immunity (1998-2003)
Member, Arthritis Foundation North Central Chapter Board of Directors (2006-2007)
Member, Oklahoma Lupus Association, Inc. (1997-2000)
Member, SLEGEN (SLE Genetics Consortium)
Guest Editor, Genes and Immunity, special issue: SLE Genetics
Coordinator, SGENE (Sjögren’s Genetics Network)
Member, OMRF Fleming Scholar Selection Committee, 2009
NIH Special Emphasis Panels (NIAMS, NIAID, NIDCR) – 2002 to present
Ad hoc reviewer: Genes and Immunity, The Journal of Rheumatology, Molecular Immunology, Arthritis and Rheumatism, Arthritis Research, American Journal of Human Genetics, Scandinavian Journal of Immunology, Human Genetics, The Journal of Laboratory and Clinical Medicine
Sjögren’s Syndrome Foundation Abstract Review Committee, American College of Rheumatology Annual Scientific Meeting, 2005 to present
Co-Chair, Sjögren’s Syndrome Study Group, American College of Rheumatology Annual Scientific Meeting, 2007-2008
American College of Rheumatology
American Society of Human Genetics
International Genetic Epidemiology Society
Sjögren’s Syndrome Foundation
Joined OMRF Scientific Staff in 2007.
My laboratory is primarily interested in identifying and characterizing genes that predispose to systemic lupus erythematosus (SLE) and Sjögren’s syndrome (SS). SLE and SS are complex rheumatic autoimmune diseases caused by the joint action of multiple genes and influenced by environmental factors. We use multidisciplinary approaches to study SLE and SS that draw on tools and concepts from immunology, genetics, biostatistics, bioinformatics, molecular biology, biochemistry, and microbiology to understand the underlying disease mechanisms.
Sjögren’s syndrome is a common, chronic, systemic disorder in which immune responses preferentially target moisture-producing glands. Dysfunction of salivary and lacrimal glands leads to the common symptoms of dry eyes and dry mouth, although multiple organ systems can also be involved and cause significant morbidity. SS may occur alone (in about 50% of patients) or in conjunction with other rheumatic autoimmune diseases such as SLE or rheumatoid arthritis. One major focus in our lab is to characterize gene expression profiles in SS using microarray technology. This powerful approach allows us to monitor the expression of thousands of genes simultaneously and identify key molecular pathways that are disregulated in patients compared to healthy controls. These studies clearly show that activation of interferon-inducible pathways are important in SS. Current studies are aimed at identifying additional pathways associated with SS and definung correlations with important clinical manifestations. A related goal is to identify genetic polymorphisms that contribute to disregulation of these pathways. For these studies and others, we have established an OMRF Sjögren’s Research Clinic. Patients and controls are extensively evaluated for clinical and laboratory features of SS. The comprehensive nature of data collection through this effort makes it a unique and extremely valuable resource for numerous studies in our lab and through collaborative efforts.
SLE is a systemic autoimmune disease with a wide spectrum of clinical manifestations involving inflammation in the joints, kidneys, brain, and other organs. Our lab has played a major role in a longstanding effort devoted to identifying genes involved in SLE. Recent projects include genome wide association studies using high-density single nucleotide polymorphism (SNP) analysis, fine mapping of several newly discovered SLE genes, functional studies aimed at understanding how these genes contribute to disease mechanism, and using a variety of alternative analytical approaches to expand the growing list of SLE genes.
Seror R, Bootsma H, Saraux A, Bowman SJ, Theander E, Brun JG, Baron G, Le Guern V, Devauchelle-Pensec V, Ramos-Casals M, Valim V, Dorner T, Tzioufas A, Gottenberg JE, Solans LR, Mandl T, Hachulla E, Sivils KL, Ng WF, Fauchais AL, Bombardieri S, Priori R, Bartoloni E, Goeb V, Praprotnik S, Sumida T, Nishiyama S, Caporali R, Kruize AA, Vollenweider C, Ravaud P, Meiners P, Brito-Zeron P, Vitali C, Mariette X, on behalf of the EULAR Sjogren's Task Force. Defining disease activity states and clinically meaningful improvement in primary Sjogren's syndrome with EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis 2014. [Abstract] EPub
Kariuki SN, Ghodke-Puranik Y, Dorschner JM, Chrabot BS, Kelly JA, Tsao BP, Kimberly RP, Alarcon-Riquelme ME, Jacob CO, Criswell LA, Sivils KL, Langefeld CD, Harley JB, Skol AD, Niewold TB. Genetic analysis of the pathogenic molecular sub-phenotype interferon-alpha identifies multiple novel loci involved in systemic lupus erythematosus. Genes Immun 2014. [Abstract] EPub
* Kottyan LC, Zoller EE, Bene J, Lu X, Kelly JA, Rupert AM, Lessard CJ, Vaughn SE, Marion M, Weirauch MT, Namjou B, Adler A, Rasmussen A, Glenn S, Montgomery CG, Hirschfield GM, Xie G, Coltescu C, Amos C, Li H, Ice JA, Nath SK, Mariette X, Simon Bowman for UK primary Sjogren's syndrome registry, Rischmueller M, Lester S, Brun JG, Goransson LG, Harboe E, Omdal R, Cunninghame-Graham DS, Vyse T, Miceli-Richard C, Brennan MT, Lessard JA, Wahren-Herlenius M, Kvarnstrom M, Illei GG, Witte T, Jonsson R, Eriksson P, Nordmark G, Wan-Fai Ng for UK primary Sjogren's syndrome registry, Anaya JM, Rhodus NL, Segal BM, Merrill JT, James JA, Guthridge JM, Scofield RH, Alarcon-Riquelme M, Bae SC, Boackle SA, Criswell LA, Gilkeson G, Kamen DL, Jacob CO, Kimberly R, Brown E, Edberg J, Alarcon GS, Reveille JD, Vila LM, Petri M, Ramsey-Goldman R, Freedman BI, Niewold T, Stevens AM, Tsao BP, Ying J, Mayes MD, Gorlova OY, Wakeland W, Radstake T, Martin E, Martin J, Siminovitch K, Moser Sivils KL, Gaffney PM, Langefeld CD, Harley JB, Kaufman KM. The IRF5-TNPO3 association with systemic lupus erythematosus (SLE) has two components that other autoimmune disorders variably share. Hum Mol Genet 2014. [Abstract] EPub
Graham RR, Cotsapas C, Davies L, Hackett R, Lessard CJ, Leon JM, Burtt NP, Guiducci C, Parkin M, Gates C, Plenge RM, Behrens TW, Wither JE, Rioux JD, Fortin PR, Graham DC, Wong AK, Vyse TJ, Daly MJ, Altshuler D, Moser KL, Gaffney PM. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 40:1059-1061, 2008. [Abstract]
Segal B, Thomas W, Rogers T, Leon JM, Hughes P, Patel D, Patel K, Novitzke J, Rohrer M, Gopalakrishnan R, Myers S, Nazmul-Hossain A, Emamian E, Huang A, Rhodus N, Moser K. Prevalence, severity, and predictors of fatigue in subjects with primary Sjogren's syndrome. Arthritis Care Res (Hoboken) 59:1780-1787, 2008. [Abstract]
Cobb BL, Lessard CJ, Harley JB, Moser KL. Genes and Sjögren's syndrome. Rheum Dis Clin North Am 34:847-868, 2008. [Abstract]
Peters AL, Plenge RM, Graham RR, Altshuler DM, Moser KL, Gaffney PM, Bishop GA. A novel polymorphism of the human CD40 receptor with enhanced function. Blood 112:1863-1871, 2008. [Abstract]
International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN), Harley JB, Alarcón-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, Tsao BP, Vyse TJ, Langefeld CD, Nath SK, Guthridge JM, Cobb BL, Mirel DB, Marion MC, Williams AH, Divers J, Wang W, Frank SG, Namjou B, Gabriel SB, Lee AT, Gregersen PK, Behrens TW, Taylor KE, Fernando M, Zidovetzki R, Gaffney PM, Edberg JC, Rioux JD, Ojwang JO, James JA, Merrill JT, Gilkeson GS, Seldin MF, Yin H, Baechler EC, Li QZ, Wakeland EK, Bruner GR, Kaufman KM, Kelly JA. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 40:204-210, 2008. [Abstract]
Arthritis & Clinical Immunology Research Program, MS 24
Oklahoma Medical Research Foundation
825 N.E. 13th Street
Oklahoma City, OK 73104
Phone: (405) 271-2534
Fax: (405) 271-3045
Astrid Rasmussen, M.D., Ph.D.
Research Assistant Member
John Ice, M.D.
Research Project Director
Cherilyn Pritchett Frazee
Research Project Nurse
Research Study Recruiter
Data Entry Clerk